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Abstract
Androgenic alopecia (AGA) is the most common alopecia that is heritable, androgen-dependent and occurs in both sexes 
with defined patterns such as Male pattern hair loss in men and Female pattern hair loss in women. AGA affects at least 50 % of 
men by the age of 50 years, and up to 70 % of all males in later life.
The aim. The research was aimed to substantiate the optimal concentration of excipients and active pharmaceutical ingre-
dients (APIs) of the emulgel intended for the topical treatment of androgenic alopecia. 
Materials and methods. In this study the samples of the emulgel bases containing different carbomer Ultrez10 con-
centrationsin the range of 0.3–0.6 % and its neutralizers (0.1 % of potassium sorbate and 0 % or 0.2 % of triethanolamine) were 
used. Colloidal and thermal stability, pH, rheological properties (structural viscosity, mechanical stability, degree of thixotropy) 
of these samples were determined. The emulgel samples with different percentages of the Serenoa repens dry extract and the 
Sophora japonica tincture were used in the biopharmaceutical studies. The samples of the emulgel with the antioxidant butyl-
hydroxytoluene different concentrations (0 %, 0.01 %, 0.02 %, 0.03 %) were used to determine acid value during 1 year of the 
emulgel storage. 
Results and discussion. It was experimentally substantiated the optimal ratio of the emulgel ingredients that provide 
good APIs release and necessary consumer properties of the semi-solid remedy like application compliance, safety and stora- 
ge stability.
Conclusions. Physicochemical, rheological and biopharmaceutical properties of emulgel bases have been studied. It was 
found that the base No. 2 (in which the concentrations of Carbomer Ultraz 10, potassium sorbate and triethanolamine are 0.3 %, 
0.1 %, 0.2 % respectively) possessed the optimal properties. Considering the results of the complete range of experimental re-
search it was developed the final formulation of the emulgel intended for AGA treatment which included the concentration of the 
APIs, neutralizers, preservatives, antioxidant and fragrance.
Keywords: androgenic alopecia, emulgel, Serenoa repens dry extract, Sophora japonica tincture, excipients, physico-
chemical and biopharmaceutical studying.
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1. Introduction
Skin diseases and pathological conditions significantly affect human psycho-emotional 
health and quality of life [1, 2]. Therefore, effective prevention and treatment of dermatological 
diseases is a significant task of contemporary medicine. Excessive hair loss or alopecia is one of the 
most common dermatological pathologies. Alopecia is a multi-etiologic disease that is divided into 
different types such as androgenic alopecia (AGA), telogen effluvium, anagen effluvium, alopecia 
areata, scarring alopecia, etc. [3, 4]. 
AGA is the most common alopecia that is heritable, androgen-dependent and occurs in both 
sexes with defined patterns such as Male pattern hair loss (MPHL) in men and Female pattern hair 
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loss (FPHL)in women. AGA affects at least 50 % of men by the age of 50 years, and up to 70 % of 
all males in later life. Epidemiological situation of FPHL is fewer in number but AGA incidence 
among women also tends to increase with age. AGA becomes a medical problem when the hair 
loss is excessive, premature and stressful to the patients, especially for women and young men [5].
In AGA, continuous miniaturization of sensitive hair follicles takes place that results in 
the conversion of thin terminal hairs into fine vellus hairs. A key role in the AGA development is 
played by the interrelationship between male sex hormones testosterone (TS) and dihydrotestos-
terone (DHT), androgen receptors (AR) in the genetically predisposed hair follicle of the temporal 
and vertex regions and 5-α-reductase (5AR) type-2 enzyme (it converts intra-follicular TS to the 
more potent DHT). Following binding to the AR, DHT leads to miniaturization and in general 
a reduction of hair growth rate [6]. Modern scientific research confirms the involvement of new 
mechanisms in AGA development, such as oxidative stress, micro-inflammation, prostaglandin 
misbalance [5, 7].
For AGA prevention and treatment different types of active pharmaceutical ingredi-
ents (APIs) are used such as synthetic capillary vasodilators (minoxidil, aminexil), 5-α-reductase 
inhibitors (finasteride, dutasteride, β-sitosterol, lauric acids), androgen receptor blockers (spirono-
lactone, cyproterone acetate, fluoride, phytosterols), cutaneous irritants (20 % Capsicum annum 
L. tincture, Turpentine essential oil, Spongilla lacustris L. powder), natural and synthetic va-
soconstrictors and vasoprotectors (aescin, quercetin, routine, troxerutin, xanthinol nicotinate, 
pentoxifylline), antioxidants of plant origin (flavonoids, hydroxycinnamic acids, phytosterols, 
carotenoids, etc.) [3, 4, 8–10].
Finasteride (FS),a specific inhibitor of the 5AR-type II enzyme, is the only United States 
Federal Drug Administration (FDA) approved oral API for AGA treatment in men. Minoxidil 
(MNX) is the other FDA approved topical API for AGA treatment, both in men and women. 
MNX apparently acts by increasing follicular vascularity as a potassium channel opener. It in-
creases the blood supply to the scalp allowing more oxygen, blood and nutrients that is why pro-
longing anagen and shortening telogen and also convertingpartially miniaturized hair follicles 
to terminal hair [7, 11]. However, these APIs are characterized with side effects and contraindi-
cations. In particular, FS weakens the erectile function and contraindicated in fertile women due 
to fetus feminization; MNX negatively affects the cardiovascular system, exacerbates hair loss 
after the treatment cessation [12]. 
Taking into account the above-mentioned, it is important to develop an effective and safe 
topical medicine with plant APIs, which would affect the main links of the AGA pathological 
process. Serenoa repens dry extract (SRDE) and Sophora japonica tincture (SJT) were chosen as 
APIsof the developing semi-solid remedy. SRDE contains a group of free and conjugated with fatty 
acids or sugars phytosterols (β-sitosterol, campesterol, stigmasterol), fatty acids (lauric, linoleic, 
linolenic, etc.). These biological active substances (BAS) reveal the anti-androgenic effect through 
5-α-reductase inhibition and blocking androgen receptors, possess antioxidant and anti-inflamma-
tory properties [13]. SJT contains a high concentration of flavonoids, which act as antioxidants and 
vasoprotectors [14]. 
Emulgel was chosen as a semi-solid dosage form of the developing medicine. Emulgels are 
emulsion gels which are hydrogels containing randomly distributed oil microdroplets. They have 
many advantages in comparison with emulsionsor gels like as:
– incorporation of hydrophobic and hydrophilic APIs;
– better stability with less concentration of emulsifiers;
– better rheological properties; 
– controlled release;
– improve patient compliance and suitability when medication applied on the scalp;
– ability to easily withdraw the medicineafter its application [15].
According to the results of experimental studies, the optimal ratio of emulsifiers (polysor-
bate-20, cetyl alcohol) and a gelling polymer (carbomer Ultrez 10) of the emulgel base was cho-
sen [16]. An increase in structural viscosity was observed when a preservative potassium sorbate 
was added into the base [17]. Potassium sorbate is a salt formed by a strong base and a weak acid, 
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so in an aqueous solution the substance undergoes hydrolysis and the solution becomes alkaline. 
Accordingly, potassium sorbate additionally acts as a neutralizer of the carbomer in the developed 
base [16]. Considering these observations, the next stage of our research was to find the rational 
concentrations of the carbomer and its neutralizers (potassium sorbate and triethanolamine) which 
affect the emulgel rheological properties.
Experimental studies on laboratory animals usually are carried out to substantiate the API 
concentration of semi-solid medicines when its pharmacological activity is not related to the anti-
microbial effect. However, such experiments require a large number of animals, they are time-con-
suming, expensive and contradictory to modern ethical standards. Therefore, the use of alternative 
experimental methods (biopharmaceutical, biological “in vitro”) is a promising research direction 
of the API concentration selection [16].
The emulgel contains components which are easily oxidized during storage, namely SRDE 
and pumpkin seed oil (the ingredient of the oil phase). Therefore, to extend theshelf life of the 
medicine it is necessary to use antioxidants (AO). To reduce the excipient and API oxidation, direct 
(butylhydroxytoluene, butylhydroxyanisole, tocopherols, ascorbic acid, etc.) and indirect (sodium 
EDTA, multi-basic acids) AO are used. To achieve the emulgel oxidation stability, butylhydroxy-
toluene (BHT) was chosen as AO. BHT is a synthetic analogue of tocopherol. BHT is thermostable 
in contrast to the latter. Compared to butylhydroxyanisole (which characterized with unpleasant 
phenolic odour) BHT is odourless and additionally possesses the antimicrobial properties [18]. 
Considering the above-mentioned, at the final experimental stage of the emulgel composition de-
veloping it is important to select the BHT optimal concentration.
The aim of the research. This research was aimed to substantiate the optimal concentration 
of the excipients and the APIs of the emulgel intended for the topical AGA treatment.
2. Materials and methods
1. Samples of the emulgel base with the different concentrations of the excipients (carbopol 
Ultrez 10, potassium sorbate, triethanolamine) were used for the physico-chemical and rheological 
studying:
– 1 – 0.3 %carbomerUltrez 10, 0.1 % potassium sorbate, 0 % triethanolamine;
– 2 – 0.3 % carbomer Ultrez 10, 0.1 % potassium sorbate, 0.2 % triethanolamine;
– 3 – 0.4 % carbomer Ultrez 10, 0.1 % potassium sorbate, 0 % triethanolamine;
– 4 – 0.4 % carbomer Ultrez 10, 0.1 % potassium sorbate, 0.2 % triethanolamine;
– 5 – 0.5 % carbomer Ultrez 10, 0.1 % potassium sorbate, 0 % triethanolamine;
– 6 – 0.5 % carbomer Ultrez 10, 0.1 % potassium sorbate, 0.2 % triethanolamine;
– 7 – 0.6 % carbomer Ultrez 10, 0.1 % potassium sorbate, 0 % triethanolamine;
– 8 – 0.6 % carbomer Ultrez 10, 0.1 % potassium sorbate, 0.2 % triethanolamine.
2. Samples of the emulgel with the different APIs concentrations used for the biopharma-
ceutical studying:
– 6 samples of the emulgel containing the SRDE in the range of 1–6 % with 1 % increments;
– 5 samples of the emulgel containing the SJT different concentrations, namely 3 %, 5 %, 
7 %, 10 %, 12 %.
3. Samples of the emulgel containing the BHT different concentrations, namely0 %, 0.01 %, 
0.02 %, 0.03 %.
Basic principles of the State Pharmacopoeia of Ukraine (SPhU) 2.0 and the State Standard 
of Ukraine (SSU) No. 4765:2007 “Cosmetic creams. General technical conditions” 2008 were con-
sidered during the development of the emulgel with SRDE and SJT.
Experimental test samples of the emulgel base and emulgel were obtained with alternate 
adding of both phases to the emulsifiers with the application of 2000 r/min homogenisation speed 
during 30 min [16].
Colloidal and thermal stability, pH, rheological properties (structural viscosity, mechanical 
stability, degree of thixotropy) of the different emulgel base samples were evaluated. Biophar-
maceutical studying (BAS releasing in agar gel) was carried out in order to substantiate the APIs 
concentrations. The acid value was evaluated in order to choose the BHT concentration.
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2. 1. Colloidal and thermal stability
Colloidal stability (centrifugation test or mechanical stress) was determined with laboratory 
centrifuge (“Mechanìka precyzyjna”, Poland). The test tubes were filled with 2/3 volume (approx-
imately 9 g) of the test samples and weighed with 0.01 g accuracy. The samples then were centri-
fuged for 5 min at a speed of 5000 rpm (the relative centrifugal force was approximately 5,000 g). 
At the end of each cycle, the samples were checked to see whether there was any change [19–21]. 
Thermal stability was determined with the emulgel base samples, each of which was placed 
in glass tubes in an amount of 8–10 ml. The filled tubes were thermostated (TC-80 MG thermostat) 
at 42.5±2.5 °C for 7 days. The samples were then transferred to the refrigerator at 6±2 °C for 7 days. 
Thereafter, the test tubes were kept at room temperature for 3 days. The result was evaluated visu-
ally. If the aqueous phase formation was not observed in the glass tube the sample was considered 
as stable [19, 21].
2. 2. pH 
pH measuring was performed potentiometrically in a 10 % emulgel base aqueous mixture 
with the pH-meter EB-74 at 20 ºC (SPhU 2.0, 2.2.3) [22].
2. 3. Rheological studying 
Rheological studying of the experimental samples (structural viscosity, mechanical 
stability, the degree of thixotropy) was carried out with the Brookfield viscometer (Viscotech 
Hispania, SL), with SC4-21 spindle for chamber volume of 8.3 ml at a temperature of 20 ºC 
(SPhU 2.0, 2.2.10) [22]. A sample of 8.3 ml was placed in the chamber and the spindle was low-
ered into it, which was switched into the rotation. The structural viscosity η (MPa·s), shear stress 
τ (Pa), shear rate Dr (s-1) were measured by increasing the spindle speed from 20 to 100 rpm, 
reaching constant values at maximum rotation and subsequent reduction in rotational speed.The 
value of the experimental bases mechanical stability (MS) was determined as the ratio of the 
shear stress before the destruction (τ1) to the shear stress after the destruction (τ2) [23]:
MS=τ1/τ2.
2. 4. Biopharmaceutical studying
To carry out the biopharmaceutical studying the 2 % agar gel was prepared. Different ana-
lytical reagents for SRDE and SJT identification were used. Sudan III alcohol-glycerol solution in 
25 % amount, which reacts with fatty acids of SRDE, and 10 % of Iron (III) chloride solution in 
5 % amount, which reacts with the SJT phenolic compounds, were added to the agar gel solutions 
respectively. Prepared agar solutions were filled in Petri dishes in the amount of 30 ml. In Petri 
dishes, six holes of an 8 mm diameter were made. Agar holes were filled with the samples (0.5 g) 
and incubated in a thermostat at 37 °C for 24 hours. The BAS diffused in agar gel and formed with 
the reagents coloured zones (dark green with Iron (III) chloride and bright orange with Sudan III). 
The zone diameter was measured every hour during 6 hours, and the last measurement was carried 
out after 24 hours. If necessary (in the ellipse formation) the greater and lesser diameters were 
measured [24, 25].
2. 5. Acid value (AV)
The acid value is the number of mg of potassium hydroxide required to neutralize the free 
acid in 1 g of the substance (the sample). Recommended procedure: about 10 g of the sample 
was accurately weighed into a 250 ml flask, and 50 ml of a mixture of equal volumes of ethanol 
(~750 g/l) and ether was added, which was neutralized with potassium hydroxide (0.1 mol/l) after add-
ing 1 mL of phenolphthalein/ethanol. The mixture was titrated with potassium hydroxide (0.1 mol/l), 
constantly shaking the flask until a pink colour was obtained, which persisted for 15 seconds. The 
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where 5.611 – the mass of potassium hydroxide (mg) that is equivalent to 1 ml of 0.1 M potassium 
hydroxide solution; V – the volume of 0.1 M potassium hydroxide solution (titrant) used, ml; m – 
emulgel sample mass, g (SPhU 2.0, 2.5.1) [22].
3. Results
Measurement results of pH, rheological properties, the colloidal and thermal stability of the 
emulgel base samples are summarised in Table 1. 
Table 1
Physicochemical and rheological characteristics of the emulgel base samples, n=5





1 4.93±0.11 1560±14 1.09 Stable Stable 
2 5.01±0.13 3560±20 1.10 Stable Stable 
3 4.90±0.10 3908±30 1.11 Stable Stable 
4 5.10±0.13 5500±13 1.29 Stable Stable 
5 4.82±0.13 5120±14 1.09 Stable Stable 
6 5.12±0.13 7600±10 1.15 Stable Stable 
7 4.77±0.16 5376±26 1.08 Stable Stable 
8 5.10±0.16 7801±20 1.25 Stable Stable 
Rheograms of the ratio “shear rate – shear stress” of the samples of the emulgel base are 
presented in Fig. 1.
Fig. 1. Rheograms of “shear rate – shear stress” correlation of the emulgel base samples
To substantiate the APIs concentrations in the emulgel formulation, the biopharmaceutical 
studies were carried out with the method of the BAS diffusion into the agar gel. Fig. 2 shows the 
diagrams of the Serenoa repens dry extract BAS penetration in the agar gel depending on the API 
concentration in the emulgel.
To select SJT concentration in the emulgel formulation, a different amount of this API was 
mixed with SRDS (3 %), the mixture was added into the base and the samples were used in bio-
pharmaceutical research. Diagrams of the Sophora japonica tincture BAS penetration in the agar 
gel depending on the API concentration in the emulgel are shown in Fig. 3.
AV is an important quality indicator because it can easily increase during the storage of the 
semi-solid dosage form, which is caused by the hydrolysis and oxidation processes of plant lipoids. 
In the emulgel formulation the BHT antioxidant effect was evaluated considering AV fluctuation 
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Fig. 2. Diagrams of the Serenoa repens dry extract BAS penetration in the agar gel depending on 
the API concentration in the emulgel
Fig. 3. Diagrams of the Sophora japonica tincture BAS penetration in the agar gel depending on 
the API concentration in the emulgel
Table 2
Study of the BHT influence on the AV during the emulgel storage, n=5
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To increase the emulgel consuming properties, 0.2 % lavender essential oil was used in the 
formulation. The selected fragrance, in addition to a pleasant floral scent, possess the antiseptic 
properties and is used in anti-dandruff remedies. 
Thus, considering the complex experimental physicochemical, rheological, biopharmaceu-
ticaland other studies the final composition of the emulgel intended for AGA treatment was devel-
oped (Table 3). The emulgel is a homogeneous, viscous mass of the yellow-green creamy consis-
tency with the distinctive scent of the lavender essential oil.
Table 3
Formulation of the emulgel intended for the AGA treatment
Ingredients Quantity, g
Serenoa repens dry extract 3.0
Sophora japonica tincture 7.0
Pumpkin seed oil 5.0
Polysorbate-20 3.0
Cetyl alcohol 3.0





Lavender essential oil 0.2
Purified water up to 100.0
The list and ratio of the emulgel ingredients are selected in such a way as to provide good 
APIs release and necessary consumer properties of the semi-solid remedy like odour, application 
compliance, safety and storage stability.
4. Discussion
As can be seen from the results of the rheological study, there is a direct correlation between 
increasing the structural viscosity and the carbomer concentration. Samples No. 1, 3, 5 and 7 with-
Continuation of Table 2
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out 0.2 % of triethanolamine possess the lower structural viscosity than samples No. 2, 4, 6 and 8 
which have the combination of both carbomer neutralizers.
The human skin surface is slightly acidic with pH in the range between 4 and 6. Such skin 
pH maintains homeostasis of the epidermal barrier and viability of resident microflora. All exper-
imental samples have pH within physiological range. However, the pH increasing of the emulgel 
samples depends on the triethanolamine presence in the formulation.
The appropriate MS value (optimum value equals 1,0) indicates the emulgel ability to with-
stand mechanical stress during processing, such as compounding or manufacturing, and storage. 
The experimental samples have different MS values, mainly No. 1, 2, 3, 5 and 7 have MS close to 
optimum; No. 4, 7 and 9, samples with the higher carbomer concentration and structural viscosity, 
have MS values from 1.15 to 1.29.
Colloidal and thermal stability of the experimental samples is not influenced by the concen-
tration or presence of the excipients in the emulgel bases since all samples are stable.
Semi-solid dosage forms (gels, creams, emulgels, etc.) in which structural viscosity is in 
the range of 2000-10000 MPa·s at 20 rpm possess optimal rheological parameters. The emulgel 
intended for application on the scalp have to be easily removedand its texture should not be heavy. 
That is why the optimum viscosity values of the developing remedyare considered in the range of 
2000–5000 MPa·s. The emulgel should exhibit pseudoplasticity. It should be dispensable from a 
container but at the same time should be spread over the scalp with light pressure [23, 26].
Study of the “shear rate – shear stress” correlation (Fig. 1) showed that all samples are 
characterized with the pseudoplastic flow and possess thixotropic properties because ofthe present 
hysteresis loops of the ascending and descending curves. The larger the hysteresis loop square, the 
easier a semi-solid medicine is applied on the skin and extruded from a container. As can be seen 
in Fig. 1, only in two samples (No. 1 and 2) the descending and ascending curves do not intersect 
and the hysteresis loops have a continuous area. However, the hysteresis loop that characterizes the 
base No 1 is situated beyond the rheological optimum. 
Thus, taking into account all the studied parameters, the sample No. 2 has improved physi-
cochemical and rheological properties, namely, the structural viscosity at 20 rpm is 3560±20 MPa·s 
(the optimum range is 2000–5000 MPa·s), MS – 1.1 (optimum = 1.0), the base has pseudoplastic 
flow and a high level of thixotropy, the ascending and descending curves do not intersect and form 
a large area of hysteresis; pH value 5.01±0.13 is within the skin physiological range.
Biopharmaceutical studies in the selection of SRDE concentrations represents that with the 
API concentration growth from 1 % to 3 % the speed of its BAS diffusion intensively increases, 
namely, for the sample with 1 % of the API the color zone changes from 8 mm (the initial diameter 
of all holes) to 16 mm, for 2 % API - to 19.5 mm, for 3 % API – to 22.5 mm respectively (Fig. 2). 
Further the API concentration increase from 4 % to 6 % does not significantly change the level of 
the BAS release since the colour zone diameters at the end of the experiment are 23.5 mm, 24 mm 
and 25 mm respectively. Considering the BAS release, it was chosen 3 % of the SRDE concen-
tration. The higher API percentage (with slightly better release rates) can significantly affect the 
rheological properties of the emulgel and would rise production expenses.
According to the results of determining the SJT concentration it was found that with API 
concentration growth from 3 % to 7 % the speed of phenolic BAS diffusion intensively increases, 
namely, for the sample with 3 % of the API the colour zone changes from 8 mm to 9.5 mm, for 5 % 
API – to 17 mm, for 7 % API – to 21 mm respectively (Fig. 3). Further concentration increase does not 
significantly change the level of the BAS release since the colour zone diameters of the experiment 
samples with 10 % and 12 % of the SJT are 22.5 mm and 23 mm respectively. Considering obtained 
results, it was selected 7 % of the SJT. In addition to the proper release, the selected amount of this 
API is sufficient for the SRDE dispersion and the mixture introduction into the emulgel base. 
Study of the emulgel stability samples during storage showed that in samples without anti-
oxidant actively increased AV. The BHT including into the formulation slowed the oxidation pro-
cesses because AV was slightly increasing during storage period. However, the AV difference in the 
emulgel samples with BHT concentration of 0.02 % and 0.03 % was insignificant compared with 
0.01 % percentage of AO. Therefore, considering the emulgel stability in the process of storage, 
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its safety when cutaneously applied and the excipient economical use, it was chosen 0.02 % of the 
BHT concentration. 
Study limitations. The difficulty of carrying out the advanced in vitro biopharmaceutical 
study in order to establish the penetrating ability of emulgel bases considering the BAS quantitative 
content in dialysate.
Prospects for further research. Further research is aimed at establishing the conditions 
and shelf life of the developed emulgel.
5. Conclusions
Physicochemical and rheological studies have proved that the base No 2 (in which the 
concentrations of carbomer Ultrez 10, potassium sorbate and triethanolamine are 0.3 %, 0.1 %, 
0.2 % respectively) has optimal consuming properties: its structural viscosity is 3560±20 MPa·s, 
MS is 1.1. It possesses pseudoplastic flow and a high level of thixotropy, its pH value is within the 
skin physiological range.
1. Considering the biopharmaceutical research data concerning BAS release into agar gel, 
the rational concentrations of APIs were substantiated, namely, 3 % of Serenoa repens dry extract 
and 7 % of Sophora japonica tincture.
2. Taking into account the changes in the acid value during 1 year of the emulgel storage, it 
was selected 0.02 % of the antioxidant BHT. This AO percentage is optimal for ensuring the emul-
gel stability and safety with topical application.
3. The final formulation of the emulgel intended for AGA cutaneous treatment was devel-
oped, which has appropriate organoleptic, physicochemical and consuming properties.
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